Cerebellar ataxia and glutamic acid decarboxylase antibodies: Immunologic profile and long-term effect of immunotherapy

JAMA Neurology

Volumn 71, Issue 8, 2014, Pages 1009-1016

  Ariño, Helena ^a,b   Gresa Arribas, Nuria ^b   Blanco, Yolanda ^a,b   Martínez Hernández, Eugenia ^a,b   Sabater, Lidia ^b   Petit Pedrol, Mar ^b   Rouco, Idoia ^c   Bataller, Luis ^d   Dalmau, Josep O ^b,e,f   Saiz, Albert ^a,b   Graus, Francesc ^a,b  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL DE CRUCES   (Spain)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

^e INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; GLUTAMATE DECARBOXYLASE 67 ANTIBODY; GLYCINE RECEPTOR; IMMUNOGLOBULIN; MEMBRANE ANTIGEN; METHYLPREDNISOLONE; RITUXIMAB; UNCLASSIFIED DRUG; GLUTAMATE DECARBOXYLASE;

ADULT; AGED; ANIMAL TISSUE; ARTICLE; ATAXIC GAIT; CEREBELLAR ATAXIA; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DYSARTHRIA; EMBRYO; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNOCHEMISTRY; IMMUNOREACTIVITY; IMMUNOTHERAPY; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY CELL CULTURE; LONG TERM CARE; MALE; NERVE CELL CULTURE; NONHUMAN; NYSTAGMUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN SUBUNIT; RADIOIMMUNOASSAY; RAT; RETROSPECTIVE STUDY; STIFF MAN SYNDROME; STRUCTURED QUESTIONNAIRE; TREATMENT RESPONSE; VERY ELDERLY; BLOOD; IMMUNOLOGY; MIDDLE AGED; STIFF-PERSON SYNDROME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; CEREBELLAR ATAXIA; FEMALE; GLUTAMATE DECARBOXYLASE; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STIFF-PERSON SYNDROME; TREATMENT OUTCOME;

EID: 84905986776     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2014.1011     Document Type: Article

References (43)

1. Honnorat J, Saiz A, Giometto B, et al. Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients. Arch Neurol. 2001;58(2):225-230. (Pubitemid 32163159)
2. Saiz A, Blanco Y, Sabater L, et al. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain. 2008;131(pt 10):2553-2563.
3. Saiz A, Arpa J, Sagasta A, Casamitjana R, Zarranz JJ, Tolosa E. Autoantibodies to glutamic acid decarboxylase in three patients with dependent diabetes mellitus, and polyendocrine autoimmunity. Neurology. 1997;49(4):1026-1030.
4. Manto MU, Hampe CS, Rogemond V, Honnorat J. Respective implications of glutamate decarboxylase antibodies in stiff person syndrome and cerebellar ataxia. Orphanet J Rare Dis. 2011;6(1):3. doi:10.1186/1750-1172-6-3.
5. Burton AR, Baquet Z, Eisenbarth GS, et al. Central nervous system destruction mediated by glutamic acid decarboxylase-specific CD4+ T cells. J Immunol. 2010;184(9):4863-4870.
6. Lancaster E, Dalmau J. Neuronal autoantigens: pathogenesis, associated disorders and antibody testing. Nat Rev Neurol. 2012;8(7):380-390.
7. Boronat A, Sabater L, Saiz A, Dalmau J, Graus F. GABAB receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders. Neurology. 2011;76(9):795-800.
8. McKeon A, Martinez-Hernandez E, Lancaster E, et al. Glycine receptor autoimmune spectrum with stiff-man syndrome phenotype. JAMA Neurol. 2013;70(1):44-50.
9. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19(5):604-607.
10. Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75(8):1135-1140. (Pubitemid 39005770)
11. Lancaster E, Lai M, Peng X, et al. Antibodies to the GABAB receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol. 2010;9(1):67-76.
12. Sabater L, Höftberger R, Boronat A, Saiz A, Dalmau J, Graus F. Antibody repertoire in paraneoplastic cerebellar degeneration and small cell lung cancer. PLoS One. 2013;8(3):e60438. doi:10.1371/journal.pone.0060438.
13. McCullagh P. Generalized linear models. Eur J Oper Res. 1984;16(3):285-292.
14. Pittock SJ, Yoshikawa H, Ahlskog JE, et al. Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction. Mayo Clin Proc. 2006;81(9):1207-1214. (Pubitemid 44316286)
15. Ishida K, Mitoma H, Wada Y, et al. Selective loss of Purkinje cells in a patient with anti-glutamic acid decarboxylase antibody-associated cerebellar ataxia. J Neurol Neurosurg Psychiatry. 2007;78(2):190-192. (Pubitemid 46220221)
16. Piccolo G, Tavazzi E, Cavallaro T, Romani A, Scelsi R, Martino G. Clinico-pathological findings in a patient with progressive cerebellar ataxia, autoimmune polyendocrine syndrome, hepatocellular carcinoma and anti-GAD autoantibodies. J Neurol Sci. 2010;290(1-2):148-149.
17. Ishida K, Mitoma H, Song SY, et al. Selective suppression of cerebellar GABAergic transmission by an autoantibody to glutamic acid decarboxylase. Ann Neurol. 1999;46(2):263-267. (Pubitemid 29382886)
18. Ishida K, Mitoma H, Mizusawa H. Reversibility of cerebellar GABAergic synapse impairment induced by anti-glutamic acid decarboxylase autoantibodies. J Neurol Sci. 2008;271(1-2):186-190.
19. Virgilio R, Corti S, Agazzi P, et al. Effect of steroid treatment in cerebellar ataxia associated with anti-glutamic acid decarboxylase antibodies. J Neurol Neurosurg Psychiatry. 2009;80(1):95-96.
20. Planche V, Marques A, Ulla M, Ruivard M, Durif F. Intravenous immunoglobulin and rituximab for cerebellar ataxia with glutamic acid decarboxylase autoantibodies [published online November 12, 2013]. Cerebellum.
21. Pedroso JL, Braga-Neto P, Dutra LA, Barsottini OG. Cerebellar ataxia associated to anti-glutamic acid decarboxylase autoantibody (anti-GAD): partial improvement with intravenous immunoglobulin therapy [letter]. Arq Neuropsiquiatr. 2011;69(6):993. http://dx.doi.org/10.1590/S0004- 282X2011000700030.
22. Nociti V, Frisullo G, Tartaglione T, et al. Refractory generalized seizures and cerebellar ataxia associated with anti-GAD antibodies responsive to immunosuppressive treatment. Eur J Neurol. 2010;17(1):e5. doi:10.1111/j.1468- 1331.2009.02839.x.
23. Nanri K, Okita M, Takeguchi M, et al. Intravenous immunoglobulin therapy for autoantibody-positive cerebellar ataxia. Intern Med. 2009;48(10):783-790.
24. Lauria G, Pareyson D, Pitzolu MG, Bazzigaluppi E. Excellent response to steroid treatment in anti-GAD cerebellar ataxia. Lancet Neurol. 2003;2(10):634-635. (Pubitemid 37162573)
25. Bonnan M, Cabre P, Olindo S, Signate A, Saint-Vil M, Smadja D. Steroid treatment in four cases of anti-GAD cerebellar ataxia [in French]. Rev Neurol (Paris). 2008;164(5):427-433. (Pubitemid 351893087)
26. Bayreuther C, Hieronimus S, Ferrari P, Thomas P, Lebrun C. Auto-immune cerebellar ataxia with anti-GAD antibodies accompanied by de novo late-onset type 1 diabetes mellitus. Diabetes Metab. 2008;34(4, pt 1):386-388.
27. Vulliemoz S, Vanini G, Truffert A, Chizzolini C, Seeck M. Epilepsy and cerebellar ataxia associated with anti-glutamic acid decarboxylase antibodies. J Neurol Neurosurg Psychiatry. 2007;78(2):187-189. (Pubitemid 46220220)
28. Abele M, Weller M, Mescheriakov S, Bürk K, Dichgans J, Klockgether T. Cerebellar ataxia with glutamic acid decarboxylase autoantibodies. Neurology. 1999;52(4):857-859. (Pubitemid 29120198)
29. McFarland NR, Login IS, Vernon S, Burns TM. Improvement with corticosteroids and azathioprine in GAD65-associated cerebellar ataxia. Neurology. 2006;67(7):1308-1309. (Pubitemid 44563856)
30. McKeon A, Robinson MT, McEvoy KM, et al. Stiff-man syndrome and variants: clinical course, treatments, and outcomes. Arch Neurol. 2012;69(2):230-238.
31. Dalakas MC, Fujii M, Li M, Lutfi B, Kyhos J, McElroy B. High-dose intravenous immune globulin for stiff-person syndrome. N Engl J Med. 2001;345(26):1870-1876. (Pubitemid 33716561)
32. Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12(2):157-165.
33. Globas C, du Montcel ST, Baliko L, et al. Early symptoms in spinocerebellar ataxia type 1, 2, 3, and 6. Mov Disord. 2008;23(15):2232-2238.
34. Ye BS, Kim YD, Nam HS, Lee HS, Nam CM, Heo JH. Clinical manifestations of cerebellar infarction according to specific lobular involvement. Cerebellum. 2010;9(4):571-579.
35. Rakocevic G, Raju R, Semino-Mora C, Dalakas MC. Stiff person syndrome with cerebellar disease and high-titer anti-GAD antibodies. Neurology. 2006;67(6):1068-1070. (Pubitemid 44454608)
36. Raju R, Foote J, Banga JP, et al. Analysis of GAD65 autoantibodies in stiff-person syndrome patients. J Immunol. 2005;175(11):7755-7762. (Pubitemid 41715229)
37. Chang T, Alexopoulos H, McMenamin M, et al. Neuronal surface and glutamic acid decarboxylase autoantibodies in nonparaneoplastic stiff person syndrome. JAMA Neurol. 2013;70(9):1140-1149.
38. Hutchinson M, Waters P, McHugh J, et al. Progressive encephalomyelitis, rigidity, and myoclonus: a novel glycine receptor antibody. Neurology. 2008;71(16):1291-1292.
39. Alexopoulos H, Akrivou S, Dalakas MC. Glycine receptor antibodies in stiff-person syndrome and other GAD-positive CNS disorders. Neurology. 2013;81(22):1962-1964.
40. Brenner T, Sills GJ, Hart Y, et al. Prevalence of neurologic autoantibodies in cohorts of patients with new and established epilepsy. Epilepsia. 2013;54(6):1028-1035.
41. Piotrowicz A, Thümen A, Leite MI, Vincent A, Moser A. A case of glycine-receptor antibody-associated encephalomyelitis with rigidity andmyoclonus (PERM): clinical course, treatment and CSF findings. J Neurol. 2011;258(12):2268-2270.
42. Mas N, Saiz A, Leite MI, et al. Antiglycine-receptor encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry. 2011;82(12):1399-1401.
43. Petit-Pedrol M, Armangue T, Peng X, et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol. 2014;13(3):276-286.